Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells

Citations Over TimeTop 14% of 2012 papers

Abstract

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer insensitive to chemotherapy. Efforts are, therefore, directed toward understanding the molecular mechanisms of chemotherapy insensitivity and the development of new anticancer drugs. Ginsenoside Rh2, one of the components in ginseng saponin, has been shown to have anti-proliferative effect on human NSCLC cells and is being studied as a therapeutic drug for NSCLC. microRNAs (miRNAs) are small, non-coding RNA molecules that play a key role in cancer progression and prevention. However, the miRNA portrait of ginsenoside Rh2-treated NSCLC cells has not yet been studied. In this study, we identified a unique set of changes in the miRNA expression profile in response to Rh2 treatment in the human NSCLC cell line A549. Using miRNA microarray analysis, we identified 44 and 24 miRNAs displaying changes in expression greater than 2-fold in Rh2-treated A549 cells. In addition, using an miRNA target prediction program, we discovered that these miRNAs are predicted to have several target genes related to angiogenesis, apoptosis, chromatic modification, cell proliferation and differentiation. Thus, these results may assist in the better understanding of the anticancer mechanism of Rh2 in NSCLC.

Related Papers

• → miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1(2012)66 cited
• → Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients(2016)57 cited
• → Detection of activated K-ras in non-small cell lung cancer by membrane array: A comparison with direct sequencing(2007)9 cited
• → Expression levels of miR‑205 and miR‑506 in colon cancer tissuesand their relationships with clinicopathological features(2018)4 cited
• → Expression of RUNX3 gene and miR-363 in colorectal cancer and the relationship with clinicopathological features(2019)4 cited